Sartorius Finalizes Acquisition of MatTek

On July 1, 2025, Sartorius, a prominent player in the life science sector, announced the completion of its acquisition of MatTek Corp from the Swedish BICO Group AB. This follows an announcement earlier in April and receipt of required regulatory approvals. The acquisition aligns with Sartorius's strategy to enhance its Lab Products and Services division, expanding its cell technology offerings. The integration is expected to create synergies with Sartorius's existing drug development tools, including cell analysis instruments and AI models.

MatTek is renowned for its human cell-based microtissues and 3D models, which facilitate advanced drug development. These models replicate human tissue structures, providing more precise and cost-effective alternatives to traditional 2D cultures and reducing animal testing reliance. MatTek operates with over 80 employees across its headquarters in Ashland, Massachusetts, USA, and a production site in Bratislava, Slovakia.